子痫前期是妊娠期特有的疾病,严重威胁母婴生命安全,是孕产妇及围产期婴儿发病及死亡的重要原因。目前尚无针对其病因及发病机制的有效治疗方法。间充质干细胞(MSCs)具有自我更新、多向分化和归巢等干细胞共性,且具有低免疫原性和免疫调节作用,能分泌多种活性生物因子,同时其来源广泛、易于分离。近年其在细胞替代治疗、基因治疗、免疫抑制、器官移植及再生医学、组织工程学等领域取得了令人瞩目的成就。MSCs在子痫前期治疗上也具有广阔的应用前景。 Preeclampsia is a unique disease during pregnancy, a serious threat to mother and child life and safety, maternal and perinatal infants and death of an important cause. There is no effective treatment for its etiology and pathogenesis. Mesenchymal stem cells (MSCs) have the common features of stem cells such as self-renewal, multi-directional differentiation and homing, and have low immunogenicity and immunomodulatory effects. They can secrete a variety of active biological factors and have wide range of sources and are easy to separate. In recent years, it has made remarkable achievements in such fields as cell replacement therapy, gene therapy, immunosuppression, organ transplantation and regenerative medicine, and tissue engineering. MSCs in the treatment of preeclampsia also has broad application prospects.